 |
| Test tubes on a test tube rack Photo by Louis Reed on Unsplash |
Offering an innovative approach to annular defect closure, Barricaid is ideal for patients living with high re-herniation risks. The aim of the Barricaid annular closure device is to prevent post-operative disability, which is common among patients who undergo aggressive discectomies. Developed by Intrinsic Therapeutics, Barricaid was featured at the 2019 Congress of Neurological Surgeons (CNS) Annual Meeting.
As part of the Minimally Invasive Surgery (MIS) symposium, Dr. Robert Whitmore gave a sponsored talk on clinical and surgical outcomes associated with the Barricaid device. The device has undergone extensive testing, including a 3-year, randomized, controlled trial across European hospitals, and achieved FDA premarket approval.
In addition, Dr. Ali Araghi gave a sponsored presentation that focused on the economic and health burden posed by reoperation in the lumbar spine. This is an all-too-common situation that Barricaid, with its bone-anchored, protective approach, is specifically designed to address.
Dr. Ali Araghi’s well-attended talk was titled “Reoperations Following Lumbar Discectomy Are Associated with Worse Clinical Outcomes and Greater Socioeconomic Burden 3 Years After the Primary Procedure.”
